- Home
- HXL vs RNA Comparison
HXL vs RNA Comparison
Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXL
- RNA
- Stock Information
- Founded
- HXL 1946
- RNA 2012
- Country
- HXL United States
- RNA United States
- Employees
- HXL N/A
- RNA N/A
- Industry
- HXL Major Chemicals
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- HXL Industrials
- RNA Health Care
- Exchange
- HXL Nasdaq
- RNA Nasdaq
- Market Cap
- HXL 5.0B
- RNA 4.0B
- IPO Year
- HXL N/A
- RNA 2020
- Fundamental
- Price
- HXL $72.63
- RNA $69.93
- Analyst Decision
- HXL Buy
- RNA Buy
- Analyst Count
- HXL 9
- RNA 19
- Target Price
- HXL $71.44
- RNA $69.00
- AVG Volume (30 Days)
- HXL 1.2M
- RNA 6.3M
- Earning Date
- HXL 10-22-2025
- RNA 11-07-2025
- Dividend Yield
- HXL 0.92%
- RNA N/A
- EPS Growth
- HXL N/A
- RNA N/A
- EPS
- HXL 0.84
- RNA N/A
- Revenue
- HXL $1,876,400,000.00
- RNA $10,729,000.00
- Revenue This Year
- HXL $1.21
- RNA N/A
- Revenue Next Year
- HXL $11.37
- RNA $108.26
- P/E Ratio
- HXL $86.15
- RNA N/A
- Revenue Growth
- HXL N/A
- RNA 1.23
- 52 Week Low
- HXL $45.28
- RNA $21.51
- 52 Week High
- HXL $74.35
- RNA $70.51
- Technical
- Relative Strength Index (RSI)
- HXL 72.46
- RNA 80.15
- Support Level
- HXL $63.21
- RNA $46.29
- Resistance Level
- HXL $74.35
- RNA $72.05
- Average True Range (ATR)
- HXL 2.46
- RNA 2.34
- MACD
- HXL 1.15
- RNA 2.01
- Stochastic Oscillator
- HXL 87.29
- RNA 91.83
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.